Chargement en cours...
Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings
The HOPE-3 investigators enrolled 12,705 intermediate-risk participants in 21 countries in a 2-by-2 factorial trial. Subjects were randomized to receive a fixed dose of rosuvastatin or placebo, candesartan plus hydrochlorothiazide daily or placebo, and a third group received combination of antihyper...
Enregistré dans:
| Publié dans: | Glob Cardiol Sci Pract |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Magdi Yacoub Heart Foundation
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5584400/ https://ncbi.nlm.nih.gov/pubmed/31463302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21542/gcsp.2016.13 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|